Skip to main content
LGND logo

LGND · Ligand Pharmaceuticals Inc

$296.34 +8.33 (+2.89%)
Market Cap
$5.86B
Shares
20.04M

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed Seller Shares
2026-07-01 ANDREW REARDON 10,000
2026-06-16 STEPHEN L. SABBA 2,145
2026-06-12 JASON HAAS 6,461
2026-06-11 Aryeh Jason 4,500
2026-06-10 Aryeh Jason 5,000
2026-06-10 Aryeh Jason 500
2026-06-10 JOHN L LAMATTINA 4,519
2026-05-13 JOHN KOZARICH 1,575
2026-05-12 JOHN KOZARICH 459
2026-05-01 KOZARICH JOHN W 467
2026-04-01 KOZARICH JOHN W 467
2026-03-23 STEPHEN L. SABBA 1,000
2026-03-11 OCTAVIO ESPINOZA 3,057
2026-03-06 JOHN L LAMATTINA 2,161
2026-03-04 ANDREW REARDON 20,000
2026-03-04 OCTAVIO ESPINOZA 13,423
2026-03-03 STEPHEN L. SABBA 2,034
2026-02-02 KOZARICH JOHN W 467
2026-01-02 KOZARICH JOHN W 467
2025-12-12 OCTAVIO ESPINOZA 1,804
2025-12-01 KOZARICH JOHN W 467
2025-11-07 NANCY GRAY 6,571
2025-11-07 JOHN L LAMATTINA 4,179
2025-11-03 KOZARICH JOHN W 467
2025-10-01 KOZARICH JOHN W 467
2025-09-23 JASON M ARYEH 10,000
2025-09-17 Aryeh Jason 10,000
2025-09-02 KOZARICH JOHN W 467
2025-08-01 KOZARICH JOHN W 467
2025-07-10 KOZARICH JOHN W 934
2025-06-23 ANDREW THOMAS REARDON 500
2025-06-10 ANDREW THOMAS REARDON 500
2025-05-15 ANDREW THOMAS REARDON 1,000
2025-03-18 Sabba Stephen L 2,406
2025-03-04 Espinoza Octavio 5,000
2024-12-23 Espinoza Octavio 2,104
2024-11-27 LAMATTINA JOHN L 2,406
2024-11-12 Korenberg Matthew E 32,183
2024-09-23 Korenberg Matthew E 14,437
2024-09-23 Reardon Andrew 2,000
2024-09-20 Korenberg Matthew E 6,275
2024-09-20 Espinoza Octavio 1,275
2024-08-28 Reardon Andrew 1,500
2024-08-22 Korenberg Matthew E 18,858
2024-08-09 Korenberg Matthew E 18,245
2024-05-17 Espinoza Octavio 5,156
2024-05-16 Espinoza Octavio 2,264
2024-05-15 Espinoza Octavio 5,873
2024-05-14 Korenberg Matthew E 14,158
2024-05-13 Korenberg Matthew E 5,142
Showing 1–50 of 58 filings
Key facts CIK 886163 CUSIP 53220K504 13F (30d) 117 filings 114 filers Visit website Investor relations